Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?
about
Glucagon-like peptide analogues for type 2 diabetes mellitusThe New Era of Drug Therapy for Obesity: The Evidence and the ExpectationsIncretins and the intensivist: what are they and what does an intensivist need to know about them?Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysisDiabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem?Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemiaPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapiesThe human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.Do GLP-1-based therapies increase cancer risk?A cohort study of acute pancreatitis in relation to exenatide use.A review of gliptins in 2011.Metformin + saxagliptin for type 2 diabetes.Advances in pharmacologic therapies for type 2 diabetes.Efficacy and safety of Jentadueto® (linagliptin plus metformin).Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks.Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.Inflammation and incretins.The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.Distal gastrectomy in pancreaticoduodenectomy is associated with accelerated gastric emptying, enhanced postprandial release of GLP-1, and improved insulin sensitivity.The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.
P2860
Q24235918-EC0A27C9-4306-491E-BDB6-6403288E959AQ26827555-17734215-BCAC-444A-837B-998299DA7FBCQ26995464-10DDCA25-C3D0-460A-8F74-452A1F2EDC3DQ33767049-E9C869A4-7A91-44E7-9897-9942A00920A6Q33803413-62A47767-3CF7-4936-8173-676976F4B958Q34041974-56627745-0D30-4EAD-BDA8-EEB9B83EC5EEQ34627077-322C6AFA-DA0C-4DBE-903C-BB8826435AF0Q35902899-305260AC-BB3F-4B2C-84C3-66AC563EAE2BQ36302662-20A3D6C8-81DF-40B3-9979-B012A4DF4C9DQ36420499-FA625CD0-132B-4CB7-9E5C-4F5E12E0815BQ36845768-E69EECFC-A4B0-4C9E-A293-05264C9AC226Q37428774-2E8FD545-03C4-4953-9F5C-C8D37BA9FBC4Q37577143-F570F15D-3DEE-42C1-B643-7207951A8430Q37841739-3E15A592-1510-4A34-A20E-98DEE0FEB813Q37965612-491B2A99-04D1-4B14-BA52-BBCB5D43C175Q37965618-E5F8CF08-7ADF-4B03-831A-CA5039026255Q38072616-42C41DE3-20D1-4BE5-B8B7-74B87C547CC8Q38082848-92D7DE01-56CC-486C-80ED-D34EF41A9618Q38101993-098723BF-80DC-4284-8AE3-41D70A0BE521Q38104338-46F26D17-77AD-4536-8AAE-82DB60D4E3CDQ38255715-3F128303-A1BA-44FD-9C96-9CB6AFCD242CQ38601929-47338689-4983-4314-B3A6-3B073281387BQ38775771-F582E33B-BD96-4F62-A469-835C8CD2583FQ39469799-9F6BAAA7-1574-47D0-A851-DBD403316D88Q43224035-36B9E4AD-ACF0-4ABF-B495-9ADC83154897Q45778975-2DD52843-0B9E-476D-845E-B64C2C0BFE62Q51334791-66297774-E9A8-4A06-9CEF-2CEAFFA359CAQ51339510-87B6184A-67E7-4E0E-887F-6045773A5478
P2860
Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Glucagon-like peptide-1 therap ...... nt bystander or friendly fire?
@en
Glucagon-like peptide-1 therap ...... nt bystander or friendly fire?
@nl
type
label
Glucagon-like peptide-1 therap ...... nt bystander or friendly fire?
@en
Glucagon-like peptide-1 therap ...... nt bystander or friendly fire?
@nl
prefLabel
Glucagon-like peptide-1 therap ...... nt bystander or friendly fire?
@en
Glucagon-like peptide-1 therap ...... nt bystander or friendly fire?
@nl
P2093
P2860
P1433
P1476
Glucagon-like peptide-1 therap ...... nt bystander or friendly fire?
@en
P2093
P2860
P2888
P356
10.1007/S00125-009-1591-5
P577
2009-11-06T00:00:00Z